Status:
COMPLETED
Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
Lead Sponsor:
Pfizer
Conditions:
Asthma
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
Primary purpose of the protocol is to determine if IMA-638 prevents a mild asthma attack by a subject with mild asthma inhaling an allergen.
Eligibility Criteria
Inclusion
- generally healthy, men and women with mild allergic asthma, aged 18 to 60 years
- only asthma med is short-acting bronchodilator used not more than twice weekly
- FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen induction
Exclusion
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00410280
Start Date
March 1 2007
End Date
May 1 2008
Last Update
November 18 2014
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University of British Columbia
Vancouver, British Columbia, Canada, V5Z 1M9
2
University of British Columbia
Vancouver, British Columbia, Canada, V5Z 3J5
3
McMaster University Medical
Hamilton, Ontario, Canada, L8N 3Z5
4
Hopital Laval
Ste-Foy, Quebec, Canada, G1V 4G5